Leriglitazone

Leriglitazone
Clinical data
Other names	Hydroxypioglitazone
ATC code	A16AX23 (WHO) ;
Identifiers
	IUPAC name 5-[[4-[2-[5-(1-Hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione;
CAS Number	146062-44-4;
PubChem CID	4147757;
DrugBank	DB15021;
ChemSpider	3360070;
UNII	K824X25AYA;
KEGG	D11603;
ChEMBL	ChEMBL1267;
CompTox Dashboard (EPA)	DTXSID30399914 ;
Chemical and physical data
Formula	C19H20N2O4S
Molar mass	372.44 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3)O;
	InChI InChI=1S/C19H20N2O4S/c1-12(22)14-4-5-15(20-11-14)8-9-25-16-6-2-13(3-7-16)10-17-18(23)21-19(24)26-17/h2-7,11-12,17,22H,8-10H2,1H3,(H,21,23,24); Key:OXVFDZYQLGRLCD-UHFFFAOYSA-N;

Leriglitazone is a PPAR-gamma agonist and metabolite of the glitazone pioglitazone. It is developed for adrenomyeloneuropathy, and other neurodegenerative diseases.^[1]^[2]^[3]^[4]